拓展性同情使用临床试验用药制度的相关问题研究

doi:10.19803/j.1672-8629.2021.01.09

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (1): 47-51.
DOI: 10.19803/j.1672-8629.2021.01.09

拓展性同情使用临床试验用药制度的相关问题研究

马静, 高京宏, 刘春光^*

武警北京总队医院药剂科,北京 100027

收稿日期:2020-04-22 修回日期:2021-01-18 出版日期:2021-01-15 发布日期:2021-01-18
通讯作者: ^*刘春光,女,硕士,主管药师,药物警戒与合理用药。E-mail:liuchunguang2019@163.com
作者简介:马静,女,博士,主任医师,临床医学与卫勤学。

Issues Related to Expanded Access to Investigational Drugs for Compassionate Use

MA Jing, GAO Jinghong, LIU Chunguang^*

Department of Pharmacy,Beijing Corps Hospital of Chinese People's Armed Police Force,Beijing 100027,China

Received:2020-04-22 Revised:2021-01-18 Online:2021-01-15 Published:2021-01-18

摘要/Abstract

摘要： 目的研究国外部分国家拓展性同情使用临床试验用药制度及申请批准情况,为我国拓展性临床试验用药制度设计提供参考。方法通过查阅美国、欧盟药品监管机构发布的法规政策、技术指南、年度报告及相关文献,深入分析欧美拓展性临床试验用药的相关概念、类别、申请要求、风险获益评估等内容。结果和结论 拓展性同情使用临床试验用药是在不能通过已上市药物有效治疗严重疾病或危及生命疾病时,获得研究药物的潜在方式。美欧等地区对拓展性研究药物制定了较为完善的法规体系,因为临床试验用药并未上市,安全性和有效性证据收集不足,使用时更要保护使用者的安全,同时伦理委员会应当严格履行职责,保证患者知情同意,并对治疗方案严格审查。

关键词: 拓展性, 同情使用, 临床试验用药

Abstract: Objective To study the laws and regulations and application approval by some foreign drug regulatory agencies concerning expanded access to investigational drugs for treatment use so as to provide reference for the design of related guidelines in China.Methods By referring to the laws and regulations,technical guidelines,annual reports and relevant literature issued by drug regulatory agencies of the United States and the European Union,the relevant concepts,categories,application requirements,risk and benefit assessment of drugs used in overseas extended clinical trials were analyzed in depth.Results and Conclusion Compassionate use of clinical trial drugs is a potential way in which patients obtain research drugs when they are suffering from serious diseases or life-threatening diseases that cannot be effectively treated with marketed drugs.As research drugs are not approved into the market,evidence about their safety and efficacy is lacking.In order to ensure the safety of subjects,ethical committees need to perform their duties by conducting strict examination of treatments.

Key words: expanded access, compassionate use, clinical trials

中图分类号:

R994.11

马静, 高京宏, 刘春光. 拓展性同情使用临床试验用药制度的相关问题研究[J]. 中国药物警戒, 2021, 18(1): 47-51.

MA Jing, GAO Jinghong, LIU Chunguang. Issues Related to Expanded Access to Investigational Drugs for Compassionate Use[J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 47-51.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.2021.01.09

https://zgywjj.magtechjournal.com/CN/Y2021/V18/I1/47

参考文献

[1] FDA.Expanded access to investigational drugs for treatment use-policy[EB/OL].(2017-12-11)[2020-04-05].https://www.fda.gov/news-events/public-health-focus/expanded-access.
[2] FDA.Investigational New Drug (IND) application[EB/OL].(2009-11-05)[2020-01-22].https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application
[3] FDA.FDA determines that vast majority of all expanded access requests may proceed[EB/OL].(2019-05-20)[2020-04-10].https://www.fda.gov/news-events/expanded-access/expanded-access-information-physicians.
[4] FDA.How to submit a request (forms)[EB/OL].(2019-09-17)[2020-03-22].https://www.fda.gov/news-events/expanded-access/expanded-access-how-submit-request-forms
[5] FDA.What are the roles and responsibilities?[EB/OL].(2019-05-09)[2020-04-10].https://www.fda.gov/news-events/expanded-access/expanded-access-information-industry#RolesResponsabilites
[6] Jonathan P,Jarow MD.Expanded access to investigational drugs:the experience of the center of drug evaluation and researchover a 10-year period[J].Ther Innov Regul Sci,2016 ,11,50(6):705-709.
[7] Gilead Sciences Initiates.Two phase 3 studies of investigational antiviral remdesivir for the treatment of COVID-19[EB/OL].(2020-02-26)[2020-04-10].https://www.gilead.com/news-and-press/press-room/press-releases/2020/2/gilead-sciences-initiates-two-phase-3-studies-of-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19.
[8] FDA.Coronavirus (COVID-19) update:FDA continues to facilitate development of treatments[EB/OL].(2020-03-19)[2020-04-11].https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-facilitate-development-treatments.
[9] EMA.Guideline on compassionate use of medicinal products[EB/OL].(2007-07-19)[2020-04-10].https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-compassionate-use-medicinal-products-pursuant-article-83-regulation-ec-no-726/2004_en.pdf
[10] EMA.Conditions of use,conditions for distribution and patients targeted and conditions for safety monitoring addressed??? to member states[EB/OL].(2020-03-03)[2020-04-05].https://www.ema.europa.eu/en/documents/other/conditions-use-conditions-distri-bution-patients-targeted-conditions-safety-monitoring-adressed_en-2.pdf.
[11] EMA.Questions and answers on the compassionate use of medicines in the European Union[EB/OL].(2010-01-21)[2020-03-15].https://www.ema.europa.eu/en/documents/other/questions-answers-compassionate-use-medicines-european-union_en-0.pdf
[12] EMA.How to request an opinion[EB/OL].(2010-01-21)[2020-04-15].https://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/reg_2004_726/reg_2004_726_en.pdf.
[13] EMA.Compassionate use programmes in Europe[EB/OL].(2017-09-20)[2020-04-10].https://www.ema.europa.eu/en/documents/presentation/presentation-compassionate-use-programmes-europe-role-ema-member-states-cbouygues-ema_en.pdf.
[14] CFDA.The general office of the General Administration of the People's Republic of China openly solicits opinions on the administrative measures for the use of drugs for clinical trials with extended sympathy (Draft for Soliciting Opinions)[EB/OL].(2017-12-15)[2020-04-13].http://www.nmpa.gov.cn/WS04/CL2095/229372.html.
[15] NMPA.Law of the People's Republic of China on Pharmaceutical Administration[EB/OL].(2019-08-27)[2020-02-13].http://www.nmpa.gov.cn/WS04/CL2076/357712.html.
[16] WHO.Ebola virus disease[EB/OL].(2019-12-01)[2020-04-18]https://www.who.int/news-room/fact-sheets/detail.
[17] NHC.Special examination and approval procedures for drugs of State Food and Drug Administration[EB/OL].(2005-11-18)[2020-02-15].http://www.nhc.gov.cn/wjw/bmgz/201105/5c7bd2102c3749af968bb2816efc770e.shtml.
[18] Sun YX,Wei FF,Feng XC,et al.Evolution and development of extended use system of clinical trial drugs in the United States[J].Chinese Journal of New Drugs(中国新药杂志),2017 (16):1880-1886.
[19] Zou LM,Qi Y,Li TL.The enlightenment of E2E guidelines on post marketing risk management of innovative drugs in China[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2019,16(11):670-674.

拓展性同情使用临床试验用药制度的相关问题研究

Issues Related to Expanded Access to Investigational Drugs for Compassionate Use

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李欣颖, 包蕾, 李舒冉, 赵荣华, 孙静, 谢丹, 鲍岩岩, 郭姗姗, 崔晓兰, 耿子涵. 疏风解毒胶囊对甲型流感病毒H1N1特异性抗体的影响[J]. 中国药物警戒, 2025, 22(8): 841-850.
[2]	王馨蔚, 彭一峰, 孙静, 冀祖恩, 包蕾, 罗恒磊, 耿子涵, 张虎娟, 李舒冉, 张敬升, 郭姗姗, 崔晓兰, 赵荣华. 一叶抗流感胶囊对人冠状病毒229E感染致小鼠肺炎的影响[J]. 中国药物警戒, 2025, 22(8): 851-855.
[3]	谢锐, 孙绮悦, 李艳英, 张敬升, 赵荣华, 郭姗姗, 耿子涵, 包蕾, 高双荣, 崔晓兰, 谢丹, 孙静. 双参苓颗粒对镉中毒致小鼠慢性肾功能衰竭模型的影响[J]. 中国药物警戒, 2025, 22(8): 856-862.
[4]	陈思颖, 丁雪丽, 刘淑佳, 张晓朦, 张冰, 林志健. 中草药心脏毒性预测模型研究[J]. 中国药物警戒, 2025, 22(8): 869-875.
[5]	蔡海丽, 张晓朦, 刘亚迪, 陈莉娟, 王雨, 张冰. 基于铁死亡探讨中药防治蒽环类药物心脏毒性的机制[J]. 中国药物警戒, 2025, 22(8): 876-882.
[6]	郑海云, 王志钢, 吴宏伟, 王少南, 王斌. 基于UPLC-Q-Exactive Orbitrap HRMS的补心安眠汤体内外化学成分分析[J]. 中国药物警戒, 2025, 22(8): 883-888.
[7]	孙雅, 王旭, 孙志, 周玉冰. 脓毒症伴急性肾损伤重症患者利奈唑胺剂量分析[J]. 中国药物警戒, 2025, 22(8): 889-895.
[8]	史琪, 王建新, 王桂杰, 陆悦阳, 主佳旭, 高蕊. 清气化痰丸治疗慢性阻塞性肺疾病急性加重的系统评价[J]. 中国药物警戒, 2025, 22(8): 914-919.
[9]	应婕, 徐霄龙, 李博, 刘腾文, 刘清泉. 金花清感颗粒治疗轻型流感临床应用的Meta分析[J]. 中国药物警戒, 2025, 22(8): 920-923.
[10]	柯秀琴, 海学武. 433例羟苯磺酸钙胶囊不良反应分析[J]. 中国药物警戒, 2025, 22(8): 924-927.
[11]	梁洁. 172例抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(8): 928-932.
[12]	刘疆, 陈洁, 邱思鸿, 李娜, 周莹, 陈永刚, 罗季. 基于美国FAERS数据库的奥马环素和莫西沙星不良事件分析[J]. 中国药物警戒, 2025, 22(8): 933-936.
[13]	赵牡丹, 朱明辉, 张欢, 赵远洋, 秦靖. 1例彭氏变形杆菌致糖尿病足感染的药学监护[J]. 中国药物警戒, 2025, 22(8): 937-940.
[14]	周玗洁, 黄晓婧, 陈明月, 杜鹏强, 王爱凤. 注射用头孢哌酮舒巴坦钠致重度血小板减少2例分析[J]. 中国药物警戒, 2025, 22(8): 941-943.
[15]	陈桦宝, 刘薇, 蒋婷, 郑玲利, 李静. 盐酸纳洛酮注射液致急性戒断综合征1例分析[J]. 中国药物警戒, 2025, 22(8): 944-946.